Question to the Department of Health and Social Care:

To ask Her Majesty’s Government whether NHS patients will be able to access Nivolumab on the Cancer Drugs Fund while the National Institute for Health and Care Excellence concludes single technology appraisals of the drug for the treatment of melanoma, non-squamous lung cancer and squamous lung cancer.

In the absence of guidance from the National Institute for Health and Care Excellence, it is for commissioners to make funding decisions on new drugs and treatments based on the available evidence.